The US health regulator has concluded the prior approval inspection (PAI) of Lupin’s Aurangabad manufacturing plant.
Lupin has said in a statement that during the inspection, the US Food and Drug Administration (USFDA) issued one 483onservation.
It added that “The observation was procedural in nature and corrected during the inspection itself.”
